ALTANA Has Withdrawn the EU Marketing Authorisation Application for Daxas
ALTANA announced that it has withdrawn the European Marketing Authorisation Application (MAA) for Daxas® (roflumilast).
ALTANA Pharma has taken this decision after consulting with the EMEA today. The submission of a new MAA will be pursued, after further clinical data are available.
ALTANA Pharma is committed to continue the development of Daxas® and will pursue further clinical studies to strengthen the anti-inflammatory product profile and possible market potential of Daxas®.
The phosphodiesterase4 (PDE4)-inhibitor Daxas® (roflumilast) is an oral investigational, steroid free anti-inflammatory agent being studied for the treatment of chronic obstructive pulmonary disease (COPD) and asthma.
Organizations
Other news from the department research and development
![Newsletter](https://img.chemie.de/assets/bionity/images/newsletter.png)
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.